US5366738A
(en)
*
|
1982-07-29 |
1994-11-22 |
Merck & Co., Inc. |
Controlled release drug dispersion delivery device
|
IL92966A
(en)
*
|
1989-01-12 |
1995-07-31 |
Pfizer |
Hydrogel-operated release devices
|
US5024843A
(en)
*
|
1989-09-05 |
1991-06-18 |
Alza Corporation |
Oral hypoglycemic glipizide granulation
|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5160744A
(en)
*
|
1991-06-27 |
1992-11-03 |
Alza Corporation |
Verapmil therapy
|
PT100944B
(pt)
*
|
1991-10-10 |
2000-02-29 |
Alza Corp |
Dispositivo para o fornecimento osmotico de farmacos com paredes de materiais hidrofobicos
|
US5543154A
(en)
*
|
1991-12-27 |
1996-08-06 |
Merck & Co., Inc. |
Controlled release nifedipine delivery device
|
WO1993012765A1
(en)
*
|
1991-12-27 |
1993-07-08 |
Merck & Co., Inc. |
A controlled release drug dispersion delivery device
|
US5330762A
(en)
*
|
1992-02-27 |
1994-07-19 |
Alza Corporation |
Tandospiaine antidepressive therapy
|
EP0652745A1
(de)
*
|
1992-07-31 |
1995-05-17 |
Daratech Pty. Ltd. |
Implantate mit kontrollierter freisetzung
|
DK0661045T3
(da)
*
|
1992-09-18 |
2002-10-28 |
Yamanouchi Pharma Co Ltd |
Hydrogelpræparat med forsinket frigivelse
|
JPH06256166A
(ja)
*
|
1993-01-06 |
1994-09-13 |
▲寛▼治 ▲高▼田 |
薬物放出制御製剤
|
US6440457B1
(en)
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
CN1096862C
(zh)
|
1994-05-06 |
2002-12-25 |
辉瑞大药厂 |
阿齐霉素的控释剂型
|
US5582838A
(en)
*
|
1994-12-22 |
1996-12-10 |
Merck & Co., Inc. |
Controlled release drug suspension delivery device
|
US5654005A
(en)
*
|
1995-06-07 |
1997-08-05 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation having a preformed passageway
|
GB9523752D0
(en)
*
|
1995-11-21 |
1996-01-24 |
Pfizer Ltd |
Pharmaceutical formulations
|
US6096339A
(en)
*
|
1997-04-04 |
2000-08-01 |
Alza Corporation |
Dosage form, process of making and using same
|
GB9611328D0
(en)
*
|
1996-05-31 |
1996-08-07 |
Zeneca Ltd |
Pharmaceutical compositions
|
AU721653B2
(en)
*
|
1996-10-25 |
2000-07-13 |
Supernus Pharmaceuticals, Inc. |
Soluble form osmotic dose delivery system
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
EP1027888B1
(de)
*
|
1999-02-10 |
2009-06-10 |
Pfizer Products Inc. |
Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
|
US6228392B1
(en)
*
|
1999-04-29 |
2001-05-08 |
Gene Tools, Llc |
Osmotic delivery composition, solution, and method
|
US6251432B1
(en)
*
|
1999-07-01 |
2001-06-26 |
Abbott Laboratories |
Sustained release dosage form unit having latex coating and method of making the same
|
EP1239839A2
(de)
|
1999-12-23 |
2002-09-18 |
Pfizer Products Inc. |
Durch hydrogel gesteuerte mehrschichtige dosierungsform enthaltend sertralin
|
CN1402632A
(zh)
|
1999-12-23 |
2003-03-12 |
辉瑞产品公司 |
水凝胶驱动的药物剂型
|
EP1712222A3
(de)
|
1999-12-23 |
2012-06-20 |
Pfizer Products Inc. |
Arzneizusammensetzung mit erhöhter Arzneistoffkonzentration
|
US6753011B2
(en)
|
2000-01-14 |
2004-06-22 |
Osmotica Corp |
Combined diffusion/osmotic pumping drug delivery system
|
US6352721B1
(en)
|
2000-01-14 |
2002-03-05 |
Osmotica Corp. |
Combined diffusion/osmotic pumping drug delivery system
|
US6669954B2
(en)
|
2000-01-25 |
2003-12-30 |
John R. Crison |
Controlled release of drugs
|
US6361225B1
(en)
|
2000-06-13 |
2002-03-26 |
Eastman Kodak Company |
Apparatus for providing a photochemical reaction
|
US6309810B1
(en)
|
2000-06-13 |
2001-10-30 |
Eastman Kodak Company |
Photochemical delivery article and method of use
|
US6296993B1
(en)
|
2000-06-13 |
2001-10-02 |
Eastman Kodak Company |
Method of providing digitized photographic image
|
US20030086972A1
(en)
*
|
2000-08-09 |
2003-05-08 |
Appel Leah E. |
Hydrogel-driven drug dosage form
|
US6770721B1
(en)
*
|
2000-11-02 |
2004-08-03 |
Surface Logix, Inc. |
Polymer gel contact masks and methods and molds for making same
|
CA2437967A1
(en)
*
|
2001-02-15 |
2002-08-22 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Novel ophthalmic compositions
|
US20030157166A1
(en)
*
|
2001-03-16 |
2003-08-21 |
Chen Chih Ming |
Controlled release sulfonylurea formulation
|
US20030008007A1
(en)
*
|
2001-04-23 |
2003-01-09 |
Jose Gutierrez-Rocca |
Release pharmaceutical construct for gastric retention
|
US20040062804A1
(en)
*
|
2001-09-28 |
2004-04-01 |
Der-Yang Lee |
Modified release dosage forms
|
MXPA04003807A
(es)
*
|
2001-11-30 |
2004-07-30 |
Pfizer Prod Inc |
Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
DE60322665D1
(de)
|
2002-02-01 |
2008-09-18 |
Pfizer Prod Inc |
Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
|
US7125563B2
(en)
*
|
2002-04-12 |
2006-10-24 |
Dava Pharmaceuticals, Inc. |
Sustained release pharmaceutical preparations and methods for producing the same
|
AU2003224358A1
(en)
*
|
2002-05-06 |
2003-11-17 |
Ranbaxy Laboratories Limited |
Monocompartment osmotic controlled drug delivery system
|
ATE373472T1
(de)
*
|
2002-07-29 |
2007-10-15 |
Alza Corp |
Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
US9107804B2
(en)
|
2002-12-10 |
2015-08-18 |
Nortec Development Associates, Inc. |
Method of preparing biologically active formulations
|
UY28326A1
(es)
*
|
2003-05-22 |
2004-06-30 |
Osmotica Argentina S A |
Dispositivo de ruptura de liberacion controlada con un pasaje preformado
|
US8029822B2
(en)
|
2003-05-22 |
2011-10-04 |
Osmotica Kereskedelmi és Seolgáltató KFT |
Rupturing controlled release device having a preformed passageway
|
TWI377958B
(en)
|
2003-06-26 |
2012-12-01 |
Control Delivery Sys Inc |
In-situ gelling drug delivery system
|
JP5628467B2
(ja)
|
2003-06-26 |
2014-11-19 |
シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. |
生体分解性徐放性ドラッグデリバリーシステム
|
US20050142203A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Grant Heinicke |
Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
|
CA2574976C
(en)
*
|
2004-08-02 |
2012-01-10 |
Samyang Corporation |
Biodegradable multi-block polymeric composition capable of sol-gel transition
|
WO2006054152A1
(en)
*
|
2004-11-22 |
2006-05-26 |
Ranbaxy Laboratories Limited |
Monocompartment osmotic-controlled delivery system of doxazosin
|
JP2007070344A
(ja)
*
|
2005-08-11 |
2007-03-22 |
Tsukioka:Kk |
内服薬
|
US8187639B2
(en)
*
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
US8153162B2
(en)
|
2005-09-27 |
2012-04-10 |
Tissuetech, Inc. |
Purified amniotic membrane compositions and methods of use
|
NZ543314A
(en)
*
|
2005-10-28 |
2007-08-31 |
Interag |
A delivery system where the driving substance contains the active component
|
EP1959966B1
(de)
|
2005-11-28 |
2020-06-03 |
Marinus Pharmaceuticals, Inc. |
Ganaxolon-formulierungen und verfahren zu ihrer herstellung und verwendung
|
AU2007284665A1
(en)
|
2006-08-11 |
2008-02-21 |
Payload Systems, Inc. |
High speed swelling, pressure exerting hemostatic device
|
WO2008021368A2
(en)
|
2006-08-11 |
2008-02-21 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
EP2532235A1
(de)
|
2006-09-22 |
2012-12-12 |
Pharmacyclics, Inc. |
Hemmer der Bruton-Tyrosinkinase
|
US20080127272A1
(en)
*
|
2006-11-28 |
2008-05-29 |
Brian John Cragun |
Aggregation of Multiple Media Streams to a User
|
US8812637B2
(en)
|
2006-11-28 |
2014-08-19 |
International Business Machines Corporation |
Aggregation of multiple media streams to a user
|
US8637080B2
(en)
|
2007-06-28 |
2014-01-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Rupturing controlled release device comprising a subcoat
|
JP5411141B2
(ja)
|
2007-09-10 |
2014-02-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
KR20100136967A
(ko)
*
|
2008-02-15 |
2010-12-29 |
썬 파마 어드밴스트 리서치 컴패니 리미티드 |
파열 효과가 감소된 방출 제어 경구 정제
|
WO2010027875A2
(en)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
ES2559029T3
(es)
|
2009-04-24 |
2016-02-10 |
Tissue Tech, Inc. |
Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
|
PT2442791T
(pt)
|
2009-06-16 |
2020-02-06 |
Pfizer |
Formas farmacêuticas de apixaban
|
US20130029970A1
(en)
|
2009-07-10 |
2013-01-31 |
Ironwood Pharmaceuticals, Inc |
CB Receptor Agonists
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
CN106913902A
(zh)
|
2009-11-09 |
2017-07-04 |
聚光灯技术合伙有限责任公司 |
多糖基水凝胶
|
CN107033368A
(zh)
|
2009-11-09 |
2017-08-11 |
聚光灯技术合伙有限责任公司 |
碎裂水凝胶
|
AR079492A1
(es)
|
2009-12-23 |
2012-02-01 |
Ironwood Pharmaceuticals Inc |
Moduladores de crth2
|
WO2011100324A1
(en)
|
2010-02-09 |
2011-08-18 |
Ironwood Pharmaceuticals Inc. |
Cannabinoid receptor agonists
|
US20130178453A1
(en)
|
2010-02-09 |
2013-07-11 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid Agonists
|
US20130178475A1
(en)
|
2010-03-17 |
2013-07-11 |
Ironwood Pharmaceuticals, Inc. |
sGC STIMULATORS
|
WO2011118454A1
(ja)
*
|
2010-03-23 |
2011-09-29 |
リンテック株式会社 |
固形製剤
|
ES2602475T3
(es)
|
2010-04-15 |
2017-02-21 |
Tracon Pharmaceuticals, Inc. |
Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
|
PL2563776T3
(pl)
|
2010-04-27 |
2017-01-31 |
Calcimedica Inc |
Związki, które modulują wewnątrzkomórkowy wapń
|
US8754219B2
(en)
|
2010-04-27 |
2014-06-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CA3240281A1
(en)
|
2010-06-03 |
2011-12-08 |
Pharmacyclics Llc |
Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
|
JP5860459B2
(ja)
|
2010-06-30 |
2016-02-16 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
sGC刺激薬
|
WO2012009134A1
(en)
|
2010-07-12 |
2012-01-19 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
US20130216552A1
(en)
|
2010-07-12 |
2013-08-22 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
CN103180316A
(zh)
|
2010-08-27 |
2013-06-26 |
钙医学公司 |
调节细胞内钙的化合物
|
CN103402515B
(zh)
|
2010-11-09 |
2017-05-17 |
铁木医药有限公司 |
sGC刺激剂
|
US9526770B2
(en)
|
2011-04-28 |
2016-12-27 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
WO2012170905A1
(en)
|
2011-06-10 |
2012-12-13 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
MX365393B
(es)
|
2011-09-13 |
2019-05-31 |
Pharmacyclics Llc |
Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
|
WO2013101830A1
(en)
|
2011-12-27 |
2013-07-04 |
Ironwood Pharmaceuticals, Inc. |
2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
CN107982266B
(zh)
|
2012-01-06 |
2021-07-30 |
H.隆德贝克有限公司 |
氨基甲酸酯化合物及其制备和使用方法
|
US9046085B2
(en)
*
|
2012-03-14 |
2015-06-02 |
Eden Medical, Inc. |
Miniature pumps
|
WO2013155422A1
(en)
|
2012-04-12 |
2013-10-17 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating alopecia and acne
|
CN104736178A
(zh)
|
2012-06-04 |
2015-06-24 |
药品循环公司 |
布鲁顿酪氨酸激酶抑制剂的晶形
|
CA2878163A1
(en)
|
2012-07-11 |
2014-01-16 |
Tissuetech, Inc. |
Compositions containing hc-ha/ptx3 complexes and methods of use thereof
|
WO2014047111A1
(en)
|
2012-09-18 |
2014-03-27 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
EP2897953B8
(de)
|
2012-09-19 |
2019-06-26 |
Cyclerion Therapeutics, Inc. |
Sgc-stimulatoren
|
DK2900674T3
(en)
|
2012-09-28 |
2017-07-03 |
Univ Washington Through Its Center For Commercialization |
RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US10172791B2
(en)
*
|
2013-03-14 |
2019-01-08 |
Massachusetts Institute Of Technology |
Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
|
US9555007B2
(en)
*
|
2013-03-14 |
2017-01-31 |
Massachusetts Institute Of Technology |
Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
|
RS59981B1
(sr)
|
2013-03-15 |
2020-03-31 |
Cyclerion Therapeutics Inc |
Sgc stimulatori
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
GB201319791D0
(en)
*
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
JP6345786B2
(ja)
|
2013-12-05 |
2018-06-20 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼの阻害剤
|
JP2016540017A
(ja)
|
2013-12-11 |
2016-12-22 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
sGC刺激物質
|
CN104971414A
(zh)
*
|
2014-04-01 |
2015-10-14 |
黄震山 |
药物缓释器
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
CN107406421A
(zh)
|
2014-09-17 |
2017-11-28 |
铁木医药有限公司 |
sGC刺激物
|
AU2015317824A1
(en)
|
2014-09-17 |
2017-03-23 |
Cyclerion Therapeutics, Inc. |
Pyrazole derivatives as sGC stimulators
|
WO2016044445A2
(en)
|
2014-09-17 |
2016-03-24 |
Ironwood Pharmaceuticals, Inc. |
sGC STIMULATORS
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
CA2974395C
(en)
|
2015-02-06 |
2023-08-22 |
University Of Washington |
Compounds and methods for preventing or treating sensory hair cell death
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
US20160243288A1
(en)
|
2015-02-23 |
2016-08-25 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
CA2977521C
(en)
|
2015-02-27 |
2024-03-19 |
Curtana Pharmaceuticals, Inc. |
1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of proton tyrosine kinase inhibitor
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
CN113413387A
(zh)
|
2015-05-11 |
2021-09-21 |
H.隆德贝克有限公司 |
治疗炎症或神经性疼痛的方法
|
JP2018516869A
(ja)
|
2015-05-20 |
2018-06-28 |
ティッシュテック,インク. |
上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
|
CN108135904A
(zh)
|
2015-08-31 |
2018-06-08 |
药品循环有限责任公司 |
用于治疗多发性骨髓瘤的btk抑制剂组合
|
WO2017100861A1
(en)
|
2015-12-16 |
2017-06-22 |
The Walter And Eliza Hall Institute Of Medical Research |
Inhibition of cytokine-induced sh2 protein in nk cells
|
WO2017125424A1
(en)
|
2016-01-19 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a btk inhibitor
|
CN108472259A
(zh)
|
2016-01-19 |
2018-08-31 |
詹森药业有限公司 |
包含btk抑制剂的配制品/组合物
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
WO2017176652A2
(en)
|
2016-04-04 |
2017-10-12 |
Sinopia Biosciences, Inc. |
Treating extrapyramidal syndrome using trapidil
|
EP3463576A4
(de)
|
2016-05-25 |
2020-01-15 |
Concentric Analgesics, Inc. |
Prodrugs von phenolischen trpv1-agonisten in kombination mit lokalanästhetika und vasokonstriktoren für verbesserte lokalanästhesie
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
CA3030821A1
(en)
|
2016-07-18 |
2018-01-25 |
Arthrosi Therapeutics, Inc. |
Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
|
AU2017314842B9
(en)
|
2016-08-26 |
2022-02-10 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
KR20230124760A
(ko)
|
2016-09-02 |
2023-08-25 |
사이클리온 테라퓨틱스, 인크. |
융합된 비시클릭 sGC 자극제
|
EP3538096B1
(de)
|
2016-11-08 |
2024-02-28 |
Tisento Therapeutics Inc. |
Behandlung von zns-erkrankungen mit sgc-stimulatoren
|
AU2017356887B2
(en)
|
2016-11-08 |
2022-06-30 |
Cyclerion Therapeutics, Inc. |
sGC stimulators
|
MA46866B1
(fr)
|
2016-11-16 |
2021-11-30 |
H Lundbeck As |
Une forme cristalline d'un inhibiteur de magl
|
AU2017361254B2
(en)
|
2016-11-16 |
2021-09-23 |
H. Lundbeck A/S. |
Pharmaceutical formulations
|
WO2019046731A1
(en)
|
2017-09-01 |
2019-03-07 |
University Of Washington |
CRYSTALLINE FORMS OF COMPOUNDS FOR PREVENTING OR TREATING DEATH OF SENSORY CILIC CELLS
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
JP2021532183A
(ja)
|
2018-07-27 |
2021-11-25 |
コンセントリック アナルジェジクス,インク. |
フェノール性trpv1アゴニストのpeg化プロドラッグ
|
KR20210117261A
(ko)
|
2018-12-31 |
2021-09-28 |
바이오메아 퓨전, 인크. |
메닌-mll 상호작용의 비가역적 억제제
|
CA3133093A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics, Inc. |
Nicorandil derivatives
|
CN115427403A
(zh)
|
2020-04-21 |
2022-12-02 |
H.隆德贝克有限公司 |
单酰基甘油脂肪酶抑制剂的合成
|
WO2022133064A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
WO2022150525A1
(en)
|
2021-01-06 |
2022-07-14 |
Awakn Life Sciences |
Mdma in the treatment of alcohol use disorder
|
CA3218884A1
(en)
|
2021-05-11 |
2022-11-17 |
David Nutt |
Therapeutic aminoindane compounds and compositions
|
EP4346788A2
(de)
|
2021-06-03 |
2024-04-10 |
Arcadia Medicine, Inc. |
Enantiomere entactogenzusammensetzungen und verfahren zu deren verwendung
|
AU2022325861A1
(en)
|
2021-08-11 |
2024-02-29 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
AU2022331496A1
(en)
|
2021-08-20 |
2024-02-29 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
|
WO2023028091A1
(en)
|
2021-08-23 |
2023-03-02 |
Alexander Shulgin Research Institute |
Deuterated empathogens
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
WO2024011142A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|
WO2024155719A1
(en)
|
2023-01-18 |
2024-07-25 |
Biomea Fusion, Inc. |
Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
|